Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Ibuprofen and Group A Streptococcus

This article was originally published in The Tan Sheet

Executive Summary

Ibuprofen and Group A Streptococcus: Seattle-King County Department of Public Health in conjunction with the Seattle Children's Hospital has issued a warning to area physicians to avoid using NSAIDs in children with chicken pox, "particularly where there is a suspicion of local complications," a King County press release states. Since December 1993, the hospital has treated 11 children with chicken pox who came down with necrotizing fasciitis, otherwise known as the flesh-eating bacteria. Eight of the 11 children had taken ibuprofen, a Children's Hospital spokesperson said. Doctors attending the children suspect that the NSAID may have accelerated the disease process in the children, according to the release. The Centers for Disease Control & Prevention said it is investigating the matter...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS083720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel